India's Shivalik Rasayan rises after China regulator permits drug evaluation
28/07/2023 08:04
** Shares of Shivalik Rasayan SIVA.NS rise as much as 5.2%
to 787.55 rupees, biggest intraday pct gain since June 16
** Active pharma ingredient (API)-maker says Centre for Drug
Evaluation, China, has permitted evaluation of its anti-leukemia
API Bendamustine
** Process of evaluation and approval underway - SIVA
** Trading volume at ~11,300 shares, slightly below the
30-day avg of ~12,800 shares as of 12:10 p.m. IST
** Stock last down ~1% YTD
(Reporting by Biplob Kumar Das in Bengaluru)
((Biplobkumar.das@thomsonreuters.com))
Recent news on Shivalik Rasayan
See all newsBrief: Shivalik Rasayan Ltd March-Quarter Consol Net Profit 45.3 Million Rupees
Brief: Shivalik Rasayan Says US FDA Approved API Facility At Dahej
India's Shivalik Rasayan climbs on US FDA approval for facility
India's Shivalik Rasayan up as U.S. FDA completes inspection at Gujarat factory
Brief: Shivalik Rasayan Says US FDA Completes Inspection At API Facility At Dahej Unit